REN and Hyperglycemia: The potential advantage over renin-angiotensin blockade such as telmisartan or other anti-fibrotic therapies targeting TGFß1, such as monoclonal antibodies, is the finding that CIM6PR and DPP4 interaction seems to be occurring selectively in context of high glucose and hence maximally modulated by linagliptin during hyperglycaemia.